Brain Neurorehabil.  2018 Mar;11(1):e3. 10.12786/bn.2018.11.e3.

Seven Cases of Successful Remission after Trial of Metoclopramide on Orofacial Dyskinesia of Stroke Patients: a Case Series

  • 1Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
  • 2Department of Physical Medicine and Rehabilitation, Ilsan Sarang Hospital, Goyang, Korea.


Orofacial dyskinesia is a condition caused by various diseases in which the tongue, lips, or jaws move involuntarily. Up to now, the exact mechanism for these degenerative changes in the brain remains unknown. Among various hypotheses, the most widely accepted hypothesis is that orofacial dyskinesia is caused by supersensitivity of the dopamine receptors. As a result, metoclopramide, a dopaminergic receptor blocking agent has been chosen as a treatment agent for our study. We used metoclopramide in seven stroke patients who displayed symptoms of orofacial dyskinesia following brain damage and observed an improvement in the symptoms from all patients. This case report represented new therapeutic methods and will aid in the treatment of orofacial dyskinesia.


Dyskinesias; Dopamine; Metoclopramide; Stroke Rehabilitation
Full Text Links
  • BN
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: